Published in Diabet Med on April 01, 2013
Defining the Role of Management Factors in Outcome Disparity in Pediatric T1D | NCT04614623
A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain (1988) 18.17
LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell (2001) 11.99
The three-dimensional structure of foot-and-mouth disease virus at 2.9 A resolution. Nature (1989) 5.87
Classification of rhabdovirus proteins: a proposal. J Virol (1972) 5.54
Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence. Nature (1982) 5.50
Myristylation of picornavirus capsid protein VP4 and its structural significance. Nature (1987) 5.26
Familial glucocorticoid deficiency with achalasia of the cardia and deficient tear production. Lancet (1978) 3.59
The cell attachment site on foot-and-mouth disease virus includes the amino acid sequence RGD (arginine-glycine-aspartic acid). J Gen Virol (1989) 3.53
The proteins of biologically active sub-units of vesicular stomatitis virus. J Gen Virol (1970) 3.44
Multi-disciplinary clinical study of Smith-Magenis syndrome (deletion 17p11.2) Am J Med Genet (1996) 3.17
Dissection of vesicular stomatitis virus into the infective ribonucleoprotein and immunizing components. J Gen Virol (1970) 2.85
Serological relationships between different strains of vesicular stomatis virus. J Gen Virol (1972) 2.68
Kinetic tuning of myosin via a flexible loop adjacent to the nucleotide binding pocket. J Biol Chem (1998) 2.62
Assignment of the genome segments of bluetongue virus type 1 to the proteins which they encode. Virology (1984) 2.60
The ribonucleic acids of the infective and interfering components of vesicular stomatitis virus. J Gen Virol (1967) 2.57
Chemical basis of antigenic variation in foot-and-mouth disease virus. Nature (1984) 2.52
Genetically engineered foot-and-mouth disease viruses with poly(C) tracts of two nucleotides are virulent in mice. J Virol (1993) 2.50
Presentation of vitamin D deficiency. Arch Dis Child (2004) 2.50
3'-Terminal nucleotide sequences in the genome RNA of picornaviruses. Nature (1978) 2.40
Protein covalently linked to foot-and-mouth disease virus RNA. Nature (1977) 2.35
Location of the initiation site for protein synthesis on foot-and-mouth disease virus RNA by in vitro translation of defined fragments of the RNA. J Virol (1980) 2.34
Characterisation of a rotavirus.20b. Nature (1975) 2.21
A physico-chemical sub-grouping of the mammalian picornaviruses. J Gen Virol (1973) 2.08
A re-appraisal of the biochemical map of foot-and-mouth disease virus RNA. J Gen Virol (1978) 2.06
British Paediatric and Adolescent Bone Group's position statement on vitamin D deficiency. BMJ (2012) 2.05
Hypocalcaemia and vitamin D deficiency: an important, but preventable, cause of life-threatening infant heart failure. Heart (2007) 2.04
A prospective, randomized comparison of preoperative and continuous balanced epidural or paravertebral bupivacaine on post-thoracotomy pain, pulmonary function and stress responses. Br J Anaesth (1999) 2.00
Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. Nature (1987) 2.00
The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling. Oncogene (2009) 1.97
Poly(C) in animal viral RNAs. Nature (1974) 1.95
Sequence and location of the poly C tract in aphtho- and cardiovirus RNA. Nucleic Acids Res (1979) 1.95
Model for vesicular stomatitis virus. J Virol (1972) 1.92
The antigens of vesicular stomatitis virus. I. Separation and immunogenicity of three complement-fixing components. J Immunol (1966) 1.89
Infective virus substructure from vesicular stomatitis virus. J Virol (1967) 1.89
Structural and serological evidence for a novel mechanism of antigenic variation in foot-and-mouth disease virus. Nature (1990) 1.86
Surface structure of vesicular stomatitis virus. J Gen Virol (1969) 1.82
Further physicochemical characterization of Nodamura virus. Evidence that the divided genome occurs in a single component. J Gen Virol (1978) 1.78
A foot and mouth disease syndrome in pigs caused by an enterovirus. Nature (1968) 1.74
Molecular cloning of foot and mouth disease virus genome and nucleotide sequences in the structural protein genes. Nature (1981) 1.73
An epidemic-associated episome? J Infect Dis (1972) 1.72
Antibody-complexed foot-and-mouth disease virus, but not poliovirus, can infect normally insusceptible cells via the Fc receptor. Virology (1993) 1.72
More precise location of the polycytidylic acid tract in foot and mouth disease virus RNA. J Virol (1978) 1.69
Anaesthesia and epilepsy. Br J Anaesth (2012) 1.67
An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia. Arch Ophthalmol (1997) 1.66
Presence of a covalently linked protein on calicivirus RNA. J Gen Virol (1978) 1.66
Antigenic differences between isolates of swine vesicular disease virus and their relationship to Coxsackie B5 virus. Nature (1973) 1.63
Differentiation of convalescent animals from those vaccinated against foot-and-mouth disease by a peptide ELISA. Vaccine (1999) 1.61
Non-responsiveness to a foot-and-mouth disease virus peptide overcome by addition of foreign helper T-cell determinants. Nature (1987) 1.57
The location of the ploy(C) tract in the RNA of foot-and-mouth disease virus. J Gen Virol (1976) 1.52
Biochemical analysis of a virulent and an avirulent strain of foot-and-mouth disease virus. J Gen Virol (1977) 1.52
Heterogeneity of the genome-linked protein of foot-and-mouth disease virus. J Virol (1980) 1.50
Purification and identification of the RNA-dependent RNA polymerase of foot-and-mouth disease virus. J Gen Virol (1979) 1.50
Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother (2000) 1.50
High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. Hepatology (1998) 1.50
Aggregation state and neurotoxic properties of Alzheimer beta-amyloid peptide. Neurodegeneration (1995) 1.45
Formaldehyde as an inactivant. Vaccine (1995) 1.42
Comparison of azabicyclic esters and oxadiazoles as ligands for the muscarinic receptor. J Med Chem (1991) 1.42
Mental health concerns of Canadian adolescents: a consumer's perspective. Can J Psychiatry (1996) 1.41
"Instant-mix" whole brain photon with neutron boost radiotherapy for malignant gliomas. Int J Radiat Oncol Biol Phys (1990) 1.40
Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther (1998) 1.40
Sleep habits and patterns of college students: a preliminary study. J Am Coll Health (2001) 1.40
Biochemical identification of viruses causing the 1981 outbreaks of foot and mouth disease in the UK. Nature (1981) 1.39
The antigens of vesicular stomatitis virus. II. The presence of two low molecular weight immunogens in virus suspensions. J Immunol (1966) 1.38
Characterization of recombinant human orexin receptor pharmacology in a Chinese hamster ovary cell-line using FLIPR. Br J Pharmacol (1999) 1.38
Picornaviridae. Intervirology (1974) 1.36
Antitumour activity of S-p-bromobenzylglutathione cyclopentyl diester in vitro and in vivo. Inhibition of glyoxalase I and induction of apoptosis. Biochem Pharmacol (1996) 1.36
Effects of posterior fossa decompression with and without duraplasty on Chiari malformation-associated hydromyelia. Neurosurgery (2000) 1.35
Dietary fat: exogenous determination of membrane structure and cell function. FASEB J (1991) 1.34
Autogenous vein grafting in femoropopliteal atherosclerosis: the limits of its effectiveness. Surgery (1979) 1.34
Cloning and characterization of a 72-kDa inositol-polyphosphate 5-phosphatase localized to the Golgi network. J Biol Chem (2000) 1.31
Newly recognized syndrome in the neck. J R Soc Med (1983) 1.29
Buoyant density of picornaviruses in caesium salts. J Gen Virol (1971) 1.28
A comparative chemical and serological study of the full and empty particles of foot-and mouth disease virus. J Gen Virol (1975) 1.27
NGO-promoted microcredit programs and women's empowerment in rural Bangladesh: quantitative and qualitative evidence. J Dev Areas (1998) 1.27
Host cell selection of antigenic variants of foot-and-mouth disease virus. J Gen Virol (1989) 1.26
Surface structure of foot-and-mouth disease virus. J Gen Virol (1969) 1.25
Differential precipitation of foot and mouth disease virus proteins made in vivo and in vitro by hyperimmune and virus particle guinea pig antisera. Virology (1981) 1.24
Current embryology and treatment of gastroschisis and omphalocele. Arch Surg (1966) 1.24
Tryptic peptide analysis of the structural proteins of vesicular stomatitis virus. J Gen Virol (1978) 1.24
A model for vesicular exanthema virus, the prototype of the calicivirus group. J Gen Virol (1978) 1.22
Further evidence for multiple proteins in the foot-and-mouth disease virus particle. J Gen Virol (1971) 1.22
Comparison of the antibodies elicited by the individual structural polypeptides of foot-and mouth disease and polio viruses. J Gen Virol (1979) 1.22
Constitutive activation of a single effector pathway: evidence for multiple activation states of a G protein-coupled receptor. Mol Pharmacol (1996) 1.21
Biochemical mapping of the foot-and-mouth disease virus genome. J Gen Virol (1977) 1.21
A model for foot-and-mouth disease virus. J Gen Virol (1972) 1.19
Childhood bereavement and subsequent psychiatric disorder. Br J Psychiatry (1966) 1.19
Encephalomyocarditis virus antibodies in sera from apparently normal pigs. Vet Rec (1977) 1.19
Hypoxia augments cytokine (transforming growth factor-beta (TGF-beta) and IL-1)-induced vascular endothelial growth factor secretion by human synovial fibroblasts. Clin Exp Immunol (1999) 1.19
The antigens of vesicular stomatitis virus. 3. Structure and immunogenicity of antigens derived from the virion by treatment with Tween and ether. J Immunol (1967) 1.19
Foot-and-mouth disease virus particles contain replicase protein 3D. Proc Natl Acad Sci U S A (1994) 1.18
Immunological priming with synthetic peptides of foot-and-mouth disease virus. J Gen Virol (1985) 1.18
Absence of poly (A) from the infective RNA of Nodamura virus. J Gen Virol (1976) 1.18
Kinetic and spectroscopic evidence for three actomyosin:ADP states in smooth muscle. J Biol Chem (2000) 1.18
Molecular weight of rhinovirus ribonucleic acid. J Gen Virol (1970) 1.17
Immune response to uncoupled peptides of foot-and-mouth disease virus. Immunology (1987) 1.17
Neutralizing epitopes of type O foot-and-mouth disease virus. I. Identification and characterization of three functionally independent, conformational sites. J Gen Virol (1989) 1.17
Inpatient diagnostic assessments: 1. Accuracy of structured vs. unstructured interviews. Psychiatry Res (2001) 1.17
Oligonucleotide mapping of picornavirus RNAs by two-dimensional electrophoresis. Virology (1976) 1.16
Induction of postnatal schwann cell death by the low-affinity neurotrophin receptor in vitro and after axotomy. J Neurosci (2000) 1.15
Treatment of elevated intracranial pressure in Reye syndrome. Ann Neurol (1978) 1.15